Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Martina Makrutzki"'
Autor:
Piotr Rutkowski, Wilson H. Miller, Ivana Krajsová, Christian U. Blank, Paola Queirolo, Ana Arance, Paul Lorigan, Mario Mandalà, Geke A. P. Hospers, Bart Neyns, Jacob Schachter, Vanna Chiarion Sileni, James Larkin, Martina Makrutzki, Enrique Espinosa, Alexander Guminski, Margarita Donica, Axel Hauschild, Gabriela Liszkay, Marta Nyakas, Michele Del Vecchio, Paolo A. Ascierto, Claus Garbe, Helen Gogas, Michael P. Brown
Publikováno v:
European Journal of Cancer, 107, 175-185. ELSEVIER SCI LTD
BACKGROUND: The oncogenic BRAF inhibitor vemurafenib improves outcomes for patients with advanced BRAFV600 mutation-positive melanoma compared with cytotoxic chemotherapy. Vemurafenib is now approved for use in this patient population.PATIENTS AND ME
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4770200b8acfba16c98dc5dbd5caf591
https://doi.org/10.1016/j.ejca.2018.11.018
https://doi.org/10.1016/j.ejca.2018.11.018
Autor:
Thomas Kaley, Ralf Hofheinz, A. Craig Lockhart, Mehdi Touat, Florence Joly, Jean-Yves Blay, Antoine Hollebecque, José Baselga, Franck Bielle, Jürgen Wolf, Lisa M. DeAngelis, Vicki L. Keedy, Igor Puzanov, Martina Makrutzki, Noopur Raje, Ian Chau, Vivek Subbiah, Todd Riehl, David M. Hyman, Jordi Rodon, Bethany Pitcher
Publikováno v:
Journal of Clinical Oncology
Purpose BRAFV600 mutations are frequently found in several glioma subtypes, including pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in glioblastoma. We sought to determine the activity of vemurafenib, a selective inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::301e5b034b8f93f4f618f314b55ebd44
https://doi.org/10.1200/jco.2018.78.9990
https://doi.org/10.1200/jco.2018.78.9990
Autor:
A. Hong, Martina Makrutzki, Brigitte Dréno, Bruno Labeille, Axel Hauschild, Scott W. Fosko, Frank Gilberg, Gary S. Rogers, S. Puig, J.-J. Grob, Rainer Kunstfeld, Dirk Schadendorf, David Zloty
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology, Wiley, 2020, 34 (9), pp.e533-e529. ⟨10.1111/jdv.16446⟩
Journal of the European Academy of Dermatology and Venereology, 2020, 34 (9), pp.e533-e529. ⟨10.1111/jdv.16446⟩
Journal of the European Academy of Dermatology and Venereology, Wiley, 2020, 34 (9), pp.e533-e529. ⟨10.1111/jdv.16446⟩
Journal of the European Academy of Dermatology and Venereology, 2020, 34 (9), pp.e533-e529. ⟨10.1111/jdv.16446⟩
International audience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff46846a610dd2400d783cd64cbc5b05
https://www.ncbi.nlm.nih.gov/pubmed/32277508
https://www.ncbi.nlm.nih.gov/pubmed/32277508
Autor:
Jean-Marie Michot, Antoine Hollebecque, Josep Tabernero, David M. Hyman, Heather Landau, Elena Elez, L. Veronese, Jürgen Wolf, Martin Kaiser, Jean-Yves Blay, José Baselga, Igor Puzanov, Noopur Raje, Martina Makrutzki, Bethany Pitcher, Andrew Yee, Ian Chau, Vincent Ribrag
Publikováno v:
JCO Precis Oncol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec165cadadab46250e53bae46cc17121
https://doi.org/10.1200/po.18.00070
https://doi.org/10.1200/po.18.00070
Autor:
Christian U. Blank, Jacob Schachter, Claus Garbe, Paola Queirolo, Geke A. P. Hospers, Vanna Chiarion Sileni, Helen Gogas, Michael P. Brown, Bart Neyns, Ana Arance, Martina Makrutzki, Enrique Espinosa, Michele Del Vecchio, Vladan Antic, James E. Larkin, Wilson H. Miller, Ivana Krajsová, Mario Mandalà, Susan Robson, Axel Hauschild, Paolo A. Ascierto
Publikováno v:
European Journal of Cancer, 79, 176-184. ELSEVIER SCI LTD
Background: The orally available BRAF kinase inhibitor vemurafenib is an effective and tolerable treatment option for patients with metastatic melanoma harbouring BRAF(V600) mutations. We assessed the safety of vemurafenib in a large population of pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1910f4406e05fe60a840c0b441e9987
https://doi.org/10.1016/j.ejca.2017.04.007
https://doi.org/10.1016/j.ejca.2017.04.007
Autor:
Vivek, Subbiah, Radj, Gervais, Gregory, Riely, Antoine, Hollebecque, Jean-Yves, Blay, Enriqueta, Felip, Martin, Schuler, Anthony, Gonçalves, Antonio, Italiano, Vicki, Keedy, Ian, Chau, Igor, Puzanov, Noopur S, Raje, Funda, Meric-Bernstam, Martina, Makrutzki, Todd, Riehl, Bethany, Pitcher, Jose, Baselga, David M, Hyman
Publikováno v:
JCO Precision Oncology
PURPOSE To study whether BRAF V600 mutations in non–small-cell lung cancer (NSCLC) may indicate sensitivity to the BRAF inhibitor vemurafenib, we included a cohort of patients with NSCLC in the vemurafenib basket (VE-BASKET) study. On the basis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7d8cb792e0c1d0450c316a2936f68ccb
https://pubmed.ncbi.nlm.nih.gov/32914022
https://pubmed.ncbi.nlm.nih.gov/32914022
Autor:
Funda Meric-Bernstam, José Baselga, Anthony Gonçalves, Vicki L. Keedy, Noopur Raje, Vivek Subbiah, David M. Hyman, Igor Puzanov, Enriqueta Felip, Antoine Hollebecque, Todd Riehl, Martin Schuler, Jean-Yves Blay, Radj Gervais, Martina Makrutzki, Gregory J. Riely, Bethany Pitcher, Antonio Italiano, Ian Chau
PURPOSE To study whether BRAF V600 mutations in non–small-cell lung cancer (NSCLC) may indicate sensitivity to the BRAF inhibitor vemurafenib, we included a cohort of patients with NSCLC in the vemurafenib basket (VE-BASKET) study. On the basis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58e3b1d622b8feebc7e8762b6996c6aa
https://www.ncbi.nlm.nih.gov/pubmed/32914022
https://www.ncbi.nlm.nih.gov/pubmed/32914022
Autor:
Gaetano Finocchiaro, Rodica Anghel, Hans Joerg Urban, George Fountzilas, Warren Mason, Martina Makrutzki, O. L. Chinot, Dana Cernea, François Ghiringhelli, Alba A. Brandes, Miguel Gil-Gil, Enrico Franceschi, Giuseppe Lombardi, Patrick Beauchesne, Chiedzo Mpofu, Josef Pichler, Antoine F. Carpentier, François Dubois, Vittorina Zagonel, Frank Saran, Anna K. Nowak
Publikováno v:
Oncologist
Oncologist, AlphaMed Press, In press, pp.theoncologist.2018-0290. ⟨10.1634/theoncologist.2018-0290⟩
Oncologist, AlphaMed Press, In press, pp.theoncologist.2018-0290. ⟨10.1634/theoncologist.2018-0290⟩
Background We assessed the efficacy and safety of bevacizumab (BEV) through multiple lines in patients with recurrent glioblastoma who had progressed after first-line treatment with radiotherapy, temozolomide, and BEV. Patients and Methods TAMIGA (NC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03b56aafa79f1107e7d482b6ce675ea6
https://europepmc.org/articles/PMC6459244/
https://europepmc.org/articles/PMC6459244/
Autor:
James, Larkin, Michael P, Brown, Ana M, Arance, Axel, Hauschild, Paola, Queirolo, Michele Del, Vecchio, Paolo A, Ascierto, Ivana, Krajsová, Jacob, Schachter, Bart, Neyns, Claus, Garbe, Vanna Chiarion, Sileni, Mario, Mandalà, Helen, Gogas, Enrique, Espinosa, Geke, Hospers, Paul, Lorigan, Marta, Nyakas, Alex, Guminski, Gabriela, Liszkay, Piotr, Rutkowski, Wilson, Miller, Margarita, Donica, Martina, Makrutzki, Christian, Blank
Publikováno v:
European journal of cancer (Oxford, England : 1990). 107
The oncogenic BRAF inhibitor vemurafenib improves outcomes for patients with advanced BRAFIn this open-label, multicentre study, patients with previously treated or untreated melanoma and the BRAFBetween March 2011 and January 2013, 3224 patients wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::95135ec815cf764fffa0945b82faf326
https://pubmed.ncbi.nlm.nih.gov/30580112
https://pubmed.ncbi.nlm.nih.gov/30580112
Autor:
Vivek Subbiah, Elena Elez, José Baselga, David M. Hyman, Jean Torrisi, Jean-Yves Blay, Eli L. Diamond, Benjamin H. Durham, Jürgen Wolf, Gary A. Ulaner, Bethany Pitcher, Noopur Raje, A. Craig Lockhart, Todd Riehl, Omar Abdel-Wahab, Mario E. Lacouture, Ferran Martínez-Valle, Joseph P. Erinjeri, Maria E. Arcila, Ian Chau, Igor Puzanov, Martina Makrutzki
Importance The histiocytic neoplasms Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) are highly enriched forBRAFV600 mutations and have been previously shown to be responsive to treatment with vemurafenib, an inhibitor of the BR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a6b3571a9e597d4b3ec4cceca52c2e7
https://europepmc.org/articles/PMC5844839/
https://europepmc.org/articles/PMC5844839/